RJA
VERA icon

Raymond James & Associates’s Vera Therapeutics VERA Stock Holding History

Raymond James & Associates’s Portfolio VERA Stock Details VERA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$2.06M Buy
46,547
+23,326
+100% +$885K ﹤0.01% 2206
2024
Q2 		$840K Sell
23,221
-9,277
-29% -$368K ﹤0.01% 2746
2024
Q1 		$1.4M Buy
32,498
+5,299
+19% +$189K ﹤0.01% 2387
2023
Q4 		$418K Sell
27,199
-1,346
-5% -$17.1K ﹤0.01% 3060
2023
Q3 		$391K Sell
28,545
-3,500
-11% -$60K ﹤0.01% 3036
2023
Q2 		$514K Buy
32,045
+6,760
+27% +$61.1K ﹤0.01% 2926
2023
Q1 		$196K Buy
+25,285
New +$195K ﹤0.01% 3499

Other funds holding VERA

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Raymond James & Associates's VERA Position: Q3 2024 in Review

Raymond James & Associates increased its Vera Therapeutics (VERA) stake by 100% in Q3 2024, buying an estimated $885K and bringing the position to 46,547 shares worth $2.06M. The position accounts for ﹤0.01% of the portfolio, ranked #2206.

Raymond James & Associates first reported a position in VERA in Q1 2023 and has held it in 7 quarters since. 173 funds tracked by Wall St. Rank hold VERA as of Q3 2024.

  • Raymond James & Associates held 46,547 shares of Vera Therapeutics worth $2.06M as of Q3 2024.
  • Raymond James & Associates bought 23,326 Vera Therapeutics shares in Q3 2024, an estimated $885K.
  • Vera Therapeutics made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #2206 holding.
  • Raymond James & Associates first reported a position in Vera Therapeutics in Q1 2023 and has held it in 7 quarters since.
  • 173 funds tracked by Wall St. Rank held Vera Therapeutics as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.